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Background: The safety and effectiveness of transcatheter aortic valve implantation (TAVI) has been reported in several studies, but poor results in 
some may have been due to the learning curve effect on patient selection and operator performance. The aim of the ADVANCE study was to evaluate 
the acute and long-term results of the Medtronic CoreValve System (MCV, Medtronic, Minneapolis, Minn.) implantation in a large, multi-center “real 
world” patient population in highly experienced centers, which had performed at least 40 TAVI procedures before joining the trial.
Methods: The ADVANCE study is a fully monitored, single-arm, international multicenter trial. High risk patients with severe aortic stenosis in which 
MCV implantation was considered feasible by the Heart Team were included. All primary endpoint-related events were fully adjudicated according to 
the recently released Valve Academic Research Consortium (VARC) definitions by an independent Clinical Events Committee. Subjects will be followed 
for five years.
Results: Between March 2010 and July 2011, a total of 1015 high risk patients (logistic EuroSCORE of 20 ±13%) with severe aortic stenosis 
were enrolled at 44 centers in 12 countries in Western Europe, Asia and South America. Subjects were 81 ± 6 years old and 51% were female. MCV 
implantation led to a significant acute improvement in hemodynamics with a decrease in mean and peak gradient, paralleled by an increase in the 
effective aortic valve orifice area. At 30 days, the primary endpoint of major adverse cardiac and cerebrovascular events (MACCE) occurred at a rate 
of 8.1%. Mortality rates (total and cardiac) were 4.6% and 2.3%, and the stroke rate was 2.9%. Myocardial infarctions occurred at a rate of 0.2%. 
VARC defined bleedings (life-threatening or disabling) were observed in 4.0% of patients. Six month follow-ups are ongoing but the results will be 
presented at the ACC congress.
Conclusions: The ADVANCE study - which is the largest “real world” multi-center Medtronic CoreValve trial - demonstrates the effectiveness of the 
MCV implantation in the presence of low 30-day mortality and stroke rates in high risk patients with severe aortic stenosis.
